| Q46313259 | Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a review |
| Q27012238 | Drug allergy: causes and desensitization |
| Q38168331 | Female gender as a susceptibility factor for drug-induced liver injury |
| Q38207944 | Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review |
| Q24273350 | How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion |
| Q58804131 | Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives |
| Q26800976 | New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity |
| Q43568484 | Overlapping effects of genetic variation and epigenetics on drug response: challenges of pharmacoepigenomics |
| Q28071652 | Progress in pharmacogenetics: consortiums and new strategies |
| Q39422837 | The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist |
| Q46209423 | The predictive value of the in vitro platelet toxicity assay (iPTA) for the diagnosis of hypersensitivity reactions to sulfonamides |
| Q38367620 | The role for microRNAs in drug toxicity and in safety assessment |
| Q93604507 | Toxic epidermal necrolysis: an update |